Long‑lasting GlyTR1 with immune checkpoint drugs for solid cancers
Official title: Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
Funded at Glytr Therapeutics, INC. · NIH-11179424 · Data updated 2026-11-12
This project tests whether a longer‑lasting version of GlyTR1 given with existing immune checkpoint medicines can help people with advanced, non‑resectable solid tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glytr Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project start | September 21, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,085,460 |
| NIH project number | 5R42CA285234-03 |
| Project ID | NIH-11179424 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with advanced, recurrent, or metastatic solid tumors that are not curable with surgery and who have exhausted standard treatment options.
✕Less likely to help
People whose tumors do not display the targeted glycan markers, those with early resectable cancers, or patients who cannot receive checkpoint immunotherapy (for example due to serious autoimmune disease) may not benefit.
What this research studies
From a patient perspective, researchers are developing a modified GlyTR1 drug that sticks around longer in the body and seeks out cancer‑specific sugar markers on tumor cells, and they plan to use it together with approved checkpoint immunotherapy drugs to boost the immune attack. The approach targets complex cell‑surface glycans (β1,6GlcNAc‑branched N‑glycans) that are overproduced on many solid tumors but rare on normal tissues. Extending GlyTR1's half‑life could allow less frequent dosing and better combination with PD‑1/PD‑L1 inhibitors, while lab and early clinical work will monitor safety and signs the tumors shrink. Initial work will likely include preclinical testing followed by small early‑phase human trials if safety looks acceptable.
Why it matters
Potential benefit: If successful, this could offer a new, targeted immunotherapy option that shrinks or controls advanced solid tumors that currently have few treatments.
How similar studies have gone: Immune checkpoint drugs have produced durable responses in several cancers and bispecific approaches have worked well in blood cancers, but targeting tumor‑specific glycans in combination with checkpoint blockade for solid tumors is a relatively new and not yet proven strategy.
Where this research is happening
-
Glytr Therapeutics, INC.
San Carlos, United States Active
Researchers
- Principal investigator: Demetriou, Michael — Glytr Therapeutics, INC.
- Study coordinator: Demetriou, Michael
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.